Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azidothymidine.

E Oksenhendler1

  • 1Département d'Immunopathologie et d'Hématologie, Hôpital Saint Louis, Paris, France.

Nouvelle Revue Francaise D'Hematologie
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Azidothymidine (AZT) prolongs life for patients with HIV, AIDS, and ARC. Ongoing trials are confirming its long-term effectiveness, toxicity, and potential to prevent disease progression in asymptomatic carriers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

La Revue de medecine interne·2023
Same author

Utility of anaerobic bottles for the diagnosis of bloodstream infections.

BMC infectious diseases·2020
Same author

Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). Single-center study on 37 patients in metropolitan France between 1996 and 2016.

Annales de dermatologie et de venereologie·2018
Same author

Efficacy of oral sirolimus as salvage therapy in refractory lichen planus associated with immune deficiency.

The British journal of dermatology·2018
Same author

KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.

The British journal of dermatology·2018

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Azidothymidine (AZT) is an antiretroviral drug active against Human Immunodeficiency Virus (HIV).
  • AZT has demonstrated effectiveness in prolonging life for patients diagnosed with Acquired Immunodeficiency Syndrome (AIDS) or AIDS-Related Complex (ARC).
  • The rapid introduction of AZT has prompted further investigation into its long-term effects and broader applications.

Purpose of the Study:

  • To confirm the long-term effectiveness and toxicity of Azidothymidine (AZT).
  • To evaluate the potential benefits of AZT in patients with other HIV-related conditions.
  • To determine if AZT can prevent the progression from HIV infection to ARC or AIDS in asymptomatic individuals.

Main Methods:

  • Ongoing global clinical trials are assessing the efficacy and safety of AZT.

Related Experiment Videos

  • Studies are investigating the drug's impact on various stages of HIV infection.
  • Research includes evaluating AZT's role in preventing the advancement of HIV disease.

    • Main Results:

    • Azidothymidine (AZT) is effective in prolonging life for individuals with AIDS or ARC.
    • Further data is required to fully establish long-term effectiveness and toxicity profiles.
    • The drug's potential benefits in diverse HIV-related conditions are under active investigation.

    Conclusions:

    • Azidothymidine (AZT) offers a survival benefit for patients with advanced HIV disease.
    • Continued research is essential to optimize AZT's use and understand its full therapeutic potential.
    • The role of AZT in preventing HIV disease progression requires further extensive clinical evaluation.